Perspective Therapeutics (NYSE:CATX) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 target price on the stock.

Several other equities research analysts have also issued reports on CATX. Scotiabank began coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Finally, Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Stock Down 1.5 %

Shares of Perspective Therapeutics stock opened at $2.62 on Thursday. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05. The stock has a fifty day moving average price of $3.16 and a 200-day moving average price of $7.41.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after purchasing an additional 298,778 shares during the period. State Street Corp raised its position in Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Janus Henderson Group PLC raised its position in Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares during the period. FMR LLC raised its position in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after acquiring an additional 44,174 shares during the period. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.